World Health Organization site
Skip Navigation Links

Please fill this short user satisfaction survey


Main
Note: This record shows only 22 elements of the WHO Trial Registration Data Set. To view changes that have been made to the source record, or for additional information about this trial, click on the URL below to go to the source record in the primary register.
Register: ChiCTR
Last refreshed on: 4 November 2019
Main ID:  ChiCTR1900027128
Date of registration: 2019-11-01
Prospective Registration: No
Primary sponsor: Department of Nephrology, The First Affiliated Hospital of Shandong First Medical University
Public title: Validation of Anti-Phospholipase A2 Receptor Antibody ELISA in a Chinese Cohort With Idiopathic Membranous Nephropathy: a Multicenter Observational Study
Scientific title: The Cut-off Value of Anti-Phospholipase A2 Receptor Antibody ELISA in Chinese Patients
Date of first enrolment: 2019-10-30
Target sample size: Target condition:288;Difficult condition:290
Recruitment status: Recruiting
URL:  http://www.chictr.org.cn/showproj.aspx?proj=44927
Study type:  Diagnostic test
Study design:  Sequential  
Phase:  N/A
Countries of recruitment
China
Contacts
Name: Yipeng Liu   
Address:  16766 Jingshi Road, Ji'nan, Shandong, China
Telephone: +86 13064089262
Email: liuyipeng@sdhospital.com.cn
Affiliation:  Department of Nephrology, The First Affiliated Hospital of Shandong First Medical University, Jinan, China
Name: Juan Chen   
Address:  16766 Jingshi Road, Ji'nan, Shandong, China
Telephone: +86 15966689255
Email: juanzi667@163.com
Affiliation:  Department of Nephrology, The First Affiliated Hospital of Shandong First Medical University, Jinan, China
Key inclusion & exclusion criteria
Inclusion criteria: Patients diagnosised with glomerular nephropathy according to kidney biopsy
Exclusion criteria: 1. Patients who received immunosuppressive treatment;
2. Patients with incomplete information.


Age minimum:
Age maximum:
Gender: Both
Health Condition(s) or Problem(s) studied
Membranous Nephrology
Intervention(s)
Gold Standard:Pathological diagnosis according to kidney biopsy(Chapter 7, 7.1 Evaluation of MN, KDIGO 2012);Index test:Serum PLA2R Antibody by ELISA;
Primary Outcome(s)
PLA2R antibody;
Secondary Outcome(s)
urine protein quantitation;
Secondary ID(s)
Source(s) of Monetary Support
Young Taishan Scholars Program
Secondary Sponsor(s)
Ethics review
Status: Approved
Approval date: 25/10/2018
Contact:
Lili Cao
Results
Results available:
Date Posted:
Date Completed:
URL:
Disclaimer: Trials posted on this search portal are not endorsed by WHO, but are provided as a service to our users. In no event shall the World Health Organization be liable for any damages arising from the use of the information linked to in this section. None of the information obtained through use of the search portal should in any way be used in clinical care without consulting a physician or licensed health professional. WHO is not responsible for the accuracy, completeness and/or use made of the content displayed for any trial record.
Copyright - World Health Organization - Version 3.6 - Version history Please fill this short user satisfaction survey